Han slår! – børnehavebørns fortælling om konflikter

Med afsæt i socialkonstruktivistisk og narrativ fortælle- og historieteori undersøges 10 praksisfortællinger om konflikter i børnehaven med fokus på narrativet ’Han slår!’. Undersøgelsen er båret af ideen om, at vi fortæller vores verden frem i samspil, at mening er af relationel karakter, og at børns fortællinger om konflikter kan anskues som led i deres legekulturelle interaktioner. Analysestrategisk set forstås da en bestemt dreng som både et faktisk barn og som en legekulturel figur, der agerer monomytisk som prygelknabe. En sammenstilling og tolkning af de 10 fortællinger viser, hvordan børnene bl.a. gennem emplotment skaber en verdensfortælling om børnehaven, som den pædagogiske medarbejder bliver en del af, men ikke nødvendigvis forstår og derfor heller ikke kan integrere i sine refleksioner-i-handling, men som tegner sig gennem sådanne refleksioner-over-handling, som artiklen præsenterer. Begreberne om krønike- og historieskrivning anvendes for at belyse, hvor vanskeligt det er at bestemme sandhedsværdien af hverdagskonflikter i børnehaven i forhold til parametre som fiktiv/faktisk, krønike/historie, legekulturel/sociokulturel, sandhed/løgn. Hvad foregår der her? er et spørgsmål, der vil blive besvaret forskelligt, afhængigt af hvem vi hver især tilkender retten til at agere som politi, advokat og dommer

Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia

Key Points In newly diagnosed ITP, addition of rituximab to dexamethasone yields higher sustained response rates than dexamethasone alone.</jats:p

Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat

YKL-40 regulates vascular endothelial growth factors and induces tumor proliferation. We investigated YKL-40 before and after treatment with vorinostat in 31 polycythemia vera (PV) and 16 essential thrombocythemia (ET) patients. Baseline PV patient levels were 2 times higher than in healthy controls (P < 0.0001) and 1.7 times higher than in ET (P = 0.02). A significant correlation between YKL-40 at baseline and neutrophils, CRP, LDH, JAK2V617F and platelets in PV patients was observed, as well as a significantly greater reduction of YKL-40 levels in PV patients responding to therapy. YKL-40 might be a novel marker of disease burden and progression in myeloproliferative neoplasms

Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat

YKL-40 regulates vascular endothelial growth factors and induces tumor proliferation. We investigated YKL-40 before and after treatment with vorinostat in 31 polycythemia vera (PV) and 16 essential thrombocythemia (ET) patients. Baseline PV patient levels were 2 times higher than in healthy controls (P < 0.0001) and 1.7 times higher than in ET (P = 0.02). A significant correlation between YKL-40 at baseline and neutrophils, CRP, LDH, JAK2V617F and platelets in PV patients was observed, as well as a significantly greater reduction of YKL-40 levels in PV patients responding to therapy. YKL-40 might be a novel marker of disease burden and progression in myeloproliferative neoplasms